Abstract
Cerium oxide nanoparticles (CONPs), owing to their radical scavenging property, have recently emerged as a therapeutic candidate for oxidative stress-mediated neurological diseases. However, oral and intravenous administration of CONPs is limited due to their poor physicochemical characteristics, low bioavailability, rapid systemic clearance, poor blood–brain penetration and dose-dependent toxicity. To overcome these challenges, we developed intranasal CONPs and evaluated their potential in the experimental PD model. CONPs were prepared by homogenous precipitation using tween 80 as a stabilizer and methanol/water as solvent. The optimization was done using Central Composite Design (CCD). The CONPs synthesis was confirmed by UV and FTIR. The optimized CONPs were small-sized (105.1 ± 5.78 nm), spherical (TEM), uniform (PDI, 0.119 ± 0.006) and stable (ZP, –22.7 ± 1.02 mV). Energy‐dispersive X‐ray analysis showed characteristic signals of Ce in developed CONPs. The X-ray diffraction pattern described the cubic fluorite structure and nano-crystalline nature of CONPs. The CONP anti-oxidant activity was found to be 93.60 ± 0.32% at 25 µg/mL concentration. Finally, motor manifestation studies like the forced swim test, locomotor test, akinesia, catalepsy, and muscle coordination test were conducted to assess the motor dysfunctions and behavioral activity in all four animal groups. Results of the in vivo motor manifestation studies in the haloperidol-induced PD rat model showed that co-administration of intranasal CONPs along with a half dose of levodopa resulted in significant protection, and results were significantly different from the untreated group but not significantly different from the healthy group. In conclusion, intranasal CONPs can be useful in ameliorating oxidative stress through their antioxidant effect and could be prospective therapeutics for the treatment of motor manifestations in Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Enquiries about data availability should be directed to the authors.
References
Ahamed J, Jaswanth Gowda BH, Almalki WH, Gupta N, Sahebkar A, Kesharwani P (2023) Recent advances in nanoparticle-based approaches for the treatment of brain tumors: opportunities and challenges. Eur Polym J 193:112111. https://doi.org/10.1016/J.EURPOLYMJ.2023.112111
Ahmed S, Gull A, Alam M, Aqil M, Sultana Y (2018) Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason Sonochem 41:213–226. https://doi.org/10.1016/j.ultsonch.2017.09.042
Ashhar MU, Kumar S, Ali J, Baboota S (2021) CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-parkinson effect. Chem Phys Lipids 235:105035. https://doi.org/10.1016/j.chemphyslip.2020.105035
Bailey ZS, Nilson E, Bates JA, Oyalowo A, Hockey KS, Sajja VSSS, Thorpe C, Rogers H, Dunn B, Frey AS, Billings MJ, Sholar CA, Hermundstad A, Kumar C, Vandevord PJ, Rzigalinski BA (2020) Cerium oxide nanoparticles improve outcome after in vitro and in vivo mild traumatic brain injury. J Neurotrauma 37:1452. https://doi.org/10.1089/NEU.2016.4644
Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Giunchedi P (2020) Nose-to-brain delivery of antioxidants as a potential tool for the therapy of neurological diseases. Pharmaceutics 12:1246–1266. https://doi.org/10.3390/pharmaceutics12121246
Caputo F, Clogston J, Calzolai L, Rösslein M, Prina-Mello A (2019) Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Release 299:31–43. https://doi.org/10.1016/j.jconrel.2019.02.030
Carlander U, Moto TP, Desalegn AA, Yokel RA, Johanson G (2018) Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics. Int J Nanomed 13:2631–2646. https://doi.org/10.2147/IJN.S157210
D’Angelo B, Santucci S, Benedetti E, Di Loreto S, Phani A, Falone S, Amicarelli F, Cerù M, Cimini A (2009) Cerium oxide nanoparticles trigger neuronal survival in a human Alzheimer disease model by modulating BDNF pathway. Curr Nanosci 5:167–176. https://doi.org/10.2174/157341309788185523
Danish SM, Gupta A, Khan UA, Hasan N, Ahmad FJ, Warsi MH, Abdelhaleem Ali AM, Zafar A, Jain GK (2022a) Intranasal cerium oxide nanoparticles ameliorate cognitive function in rats with Alzheimer’s via anti-oxidative pathway. Pharmaceutics 14:1–14. https://doi.org/10.3390/pharmaceutics14040756
Danish SM, Gupta A, Khan UA, Hasan N, Ahmad FJ, Warsi MH, Ali AMA, Zafar A, Jain GK (2022b) Intranasal cerium oxide nanoparticles ameliorate cognitive function in rats with Alzheimer’s via anti-oxidative pathway. Pharm 14:756. https://doi.org/10.3390/PHARMACEUTICS14040756
Das M, Patil S, Bhargava N, Kang J-F, Riedel LM, Seal S, Hickman JJ (2007) Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials 28:1918–1925. https://doi.org/10.1016/j.biomaterials.2006.11.036
De La Casa LG, Lucía C, Ruiz-Salas JC, Vicente L, Mena A (2018) Conditioned increase of locomotor activity induced by haloperidol. PLoS One 13:e0200178. https://doi.org/10.1371/journal.pone.0200178
Dhall A, Self W (2018) Cerium oxide nanoparticles: a brief review of their synthesis methods and biomedical applications. Antioxidants (basel, Switzerland). https://doi.org/10.3390/antiox7080097
Dhas N, Mehta T (2021) Intranasal delivery of chitosan decorated PLGA core /shell nanoparticles containing flavonoid to reduce oxidative stress in the treatment of Alzheimer’s disease. J Drug Deliv Sci Technol 61:1–11. https://doi.org/10.1016/j.jddst.2020.102242
Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in parkinson’s disease. J Parkinsons Dis 3:461–491. https://doi.org/10.3233/JPD-130230
Dillon CE, Billings M, Hockey KS, DeLaGarza L, Rzigalinski BA (2011) Cerium oxide nanoparticles protect against MPTP-induced dopaminergic neurodegeneration in a mouse model for Parkinson’s disease, in: Technical Proceedings of the 2011 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2011. p 451–454
Dongsar TT, Dongsar TS, Abourehab MAS, Gupta N, Kesharwani P (2023a) Emerging application of magnetic nanoparticles for breast cancer therapy. Eur Polym J 187:111898. https://doi.org/10.1016/J.EURPOLYMJ.2023.111898
Dongsar TT, Dongsar TS, Gupta N, Almalki WH, Sahebkar A, Kesharwani P (2023b) Emerging potential of 5-fluorouracil-loaded chitosan nanoparticles in cancer therapy. J Drug Deliv Sci Technol 82:104371. https://doi.org/10.1016/J.JDDST.2023.104371
Dowding JM, Song W, Bossy K, Karakoti A, Kumar A, Kim A, Bossy B, Seal S, Ellisman MH, Perkins G, Self WT, Bossy-Wetzel E (2014) Cerium oxide nanoparticles protect against Aβ-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ 21:1622–1632. https://doi.org/10.1038/cdd.2014.72
Dunnick KM, Pillai R, Pisane KL, Stefaniak AB, Sabolsky EM, Leonard SS (2015) The effect of cerium oxide nanoparticle valence state on reactive oxygen species and toxicity. Biol Trace Elem Res 106:96–107. https://doi.org/10.1007/s12011-015-0297-4
El-Awdan SA, Abdel Jaleel GA, Saleh DO (2015) Alleviation of haloperidol induced oxidative stress in rats: effects of sucrose vs grape seed extract. Bull Fac Pharm Cairo Univ 53:29–35. https://doi.org/10.1016/j.bfopcu.2015.02.004
Elnaggar YSR, Etman SM, Abdelmonsif DA, Abdallah OY (2015) Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104:3544–3556. https://doi.org/10.1002/jps.24557
Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155–170. https://doi.org/10.1016/j.brainresbull.2018.10.009
Farias IAP, Santos CCL, Xavier AL, Batista TM, Nascimento YM, Nunes JMFF, Silva PMF, Menezes-Júnior RA, Ferreira JM, Lima EO, Tavares JF, Sobral MV, Keyson D, Sampaio FC (2021) Synthesis, physicochemical characterization, antifungal activity and toxicological features of cerium oxide nanoparticles. Arab J Chem 14:102888. https://doi.org/10.1016/j.arabjc.2020.10.035
Fatima M, Karwasra R, Almalki WH, Sahebkar A, Kesharwani P (2023) Galactose engineered nanocarriers: hopes and hypes in cancer therapy. Eur Polym J 183:111759. https://doi.org/10.1016/J.EURPOLYMJ.2022.111759
Filograna R, Beltramini M, Bubacco L, Bisaglia M (2016) Anti-oxidants in Parkinson’s disease therapy: a critical point of view. Curr Neuropharmacol 14:260–271. https://doi.org/10.2174/1570159x13666151030102718
Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9:S5. https://doi.org/10.1186/1471-2202-9-S3-S5
Hasan N, Imran M, Kesharwani P, Khanna K, Karwasra R, Sharma N, Rawat S, Sharma D, Ahmad FJ, Jain GK, Bhatnagar A, Talegaonkar S (2021) Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Int J Pharm. https://doi.org/10.1016/j.ijpharm.2021.120428
Hegazy MA, Maklad HM, Samy DM, Abdelmonsif DA, El Sabaa BM, Elnozahy FY (2017) Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson’s disease in rats. Neurochem Int 108:361–371. https://doi.org/10.1016/j.neuint.2017.05.011
Honary S, Zahir F (2013) Effect of zeta potential on the properties of nano-drug delivery systems—a review (Part 2). Trop J Pharm Res 12:265–273. https://doi.org/10.4314/tjpr.v12i2.20
Iqbal N, Anastasiou A, Aslam Z, Raif EM, Do T, Giannoudis PV, Jha A (2021) Interrelationships between the structural, spectroscopic, and antibacterial properties of nanoscale (< 50 nm) cerium oxides. Sci Rep 11:20875. https://doi.org/10.1038/s41598-021-00222-9
Kalia LV, Lancet AEL (2015) Parkinson’s disease Lorraine. Lancet 24:92–98. https://doi.org/10.1016/S0140-6736(14)61393-3
Kesharwani P, Fatima M, Singh V, Sheikh A, Almalki WH, Gajbhiye V, Sahebkar A (2022) Itraconazole and difluorinated-curcumin containing chitosan nanoparticle loaded hydrogel for amelioration of onychomycosis. Biomimetics 7:206. https://doi.org/10.3390/BIOMIMETICS7040206
Kesharwani P, Sheikh A, Abourehab MAS, Salve R, Gajbhiye V (2023) A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy. J Drug Deliv Sci Technol 80:104164. https://doi.org/10.1016/J.JDDST.2023.104164
Khan UA, Parveen U, Hasan N, Ahmed MZ, Saad S, Ahmad FJ, Jain GK (2020) Parenteral sustained release lipid phase-transition system of ziprasidone: Fabrication and evaluation for schizophrenia therapy. Drug Des Devel Ther. https://doi.org/10.2147/DDDT.S247196
Kumari M, Kumari SI, Grover P (2014) Genotoxicity analysis of cerium oxide micro and nanoparticles in Wistar rats after 28 days of repeated oral administration. Mutagenesis 29:467–479. https://doi.org/10.1093/MUTAGE/GEU038
Liu Z, Parveen N, Rehman U, Aziz A, Sheikh A, Abourehab MAS, Guo W, Huang J, Wang Z, Kesharwani P (2023) Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer. Mol Cancer 22(1):1–22. https://doi.org/10.1186/S12943-022-01696-5
Minakaki G, Krainc D, Burbulla LF (2020) The convergence of alpha-synuclein, mitochondrial, and lysosomal pathways in vulnerability of midbrain dopaminergic neurons in Parkinson’s disease. Front Cell Dev Biol 8:580634. https://doi.org/10.3389/fcell.2020.580634
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J (2014) Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv 21:75–86. https://doi.org/10.3109/10717544.2013.838713
Moleavin IAT, Fifere A, Lungoci AL, Rosca I, Coroaba A, Peptanariu D, Nastasa V, Pasca SA, Bostanaru AC, Mares M, Pinteala M (2019) In vitro and in vivo antioxidant activity of the new magnetic-cerium oxide nanoconjugates. Nanomaterials 9:1–20. https://doi.org/10.3390/nano9111565
Molina RM, Konduru NV, Jimenez RJ, Pyrgiotakis G, Demokritou P, Wohlleben W, Brain JD (2014) Bioavailability, distribution and clearance of tracheally instilled, gavaged or injected cerium dioxide nanoparticles and ionic cerium. Environ Sci Nano 1:561–573. https://doi.org/10.1039/c4en00034j
Morille M, Saulnier P, Benoit J-P, Passirani C (2011) Antioxidant nanoparticles. Nanomedicine Heal Dis. https://doi.org/10.1201/B11076-8
Mustafa G, Ahuja A, Al Rohaimi AH, Muslim S, Hassan AA, Baboota S, Ali J (2015) Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. Expert Rev Neurother 15:695–710. https://doi.org/10.1586/14737175.2015.1036743
Naz S, Beach J, Heckert B, Tummala T, Pashchenko O, Banerjee T, Santra S (2017) Cerium oxide nanoparticles: a “radical” approach to neurodegenerative disease treatment. Nanomedicine (lond) 12:545–553. https://doi.org/10.2217/nnm-2016-0399
Noyce AJ, Nagy A, Acharya S, Hadavi S, Bestwick JP, Fearnley J, Lees AJ, Giovannoni G (2014) Bradykinesia-akinesia incoordination test: Validating an online keyboard test of upper limb function. PLoS One 9:e962260. https://doi.org/10.1371/journal.pone.0096260
Nunomura A, Moreira P, Lee H, Zhu X, Castellani R, Smith M, Perry G (2008) Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets 6:411–423. https://doi.org/10.2174/187152707783399201
Pardeshi CV, Belgamwar VS (2013) Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv 10:957–972. https://doi.org/10.1517/17425247.2013.790887
Park K, Park J, Lee H, Choi J, Yu WJ, Lee J (2018) Toxicity and tissue distribution of cerium oxide nanoparticles in rats by two different routes: single intravenous injection and single oral administration. Arch Pharm Res 41:1–9. https://doi.org/10.1007/s12272-018-1074-7
Parveen N, Sheikh A, Abourehab MAS, Karwasra R, Singh S, Kesharwani P (2023) Self-nanoemulsifying drug delivery system for pancreatic cancer. Eur Polym J 190:111993. https://doi.org/10.1016/J.EURPOLYMJ.2023.111993
Paul A, Yadav KS (2020) Parkinson’s disease: current drug therapy and unraveling the prospects of nanoparticles. J Drug Deliv Sci Technol 34:91–100. https://doi.org/10.1016/j.jddst.2020.101790
Pochapski DJ, Carvalho Dos Santos C, Leite GW, Pulcinelli SH, Santilli CV (2021) Zeta potential and colloidal stability predictions for inorganic nanoparticle dispersions: effects of experimental conditions and electrokinetic models on the interpretation of results. Langmuir 37:13379–13389. https://doi.org/10.1021/acs.langmuir.1c02056
Prabaharan DMDM, Sadaiyandi K, Mahendran M, Sagadevan S (2016) Structural, optical, morphological and dielectric properties of cerium oxide nanoparticles. Mater Res 19:478–482. https://doi.org/10.1590/1980-5373-MR-2015-0698
Qamar Z, Ashhar MU, Annu, Qizilibash FF, Sahoo PK, Ali A, Ali J, Baboota S (2021) Lipid nanocarrier of selegiline augmented anti-Parkinson’s effect via P-gp modulation using quercetin. Int J Pharm 609:121–131. https://doi.org/10.1016/j.ijpharm.2021.121131
Sandhua KS, Cranab A (2013) Evaluation of Anti Parkinson’S activity of Nigella sativa (Kalonji) seeds in chlorpromazineinduced experimental animal model. Int J Pharm Pharm Sci 5:884–888
Sharma D, Singh S, Kumar P, Jain GK, Aggarwal G, Almalki WH, Kesharwani P (2023) Mechanisms of photodynamic therapy. Nanomater Photodyn Ther. https://doi.org/10.1016/B978-0-323-85595-2.00017-7
Singh N, Cohen CA, Rzigalinski BA (2007) Treatment of neurodegenerative disorders with radical nanomedicine. Ann NY Acad Sci 1122:219–230. https://doi.org/10.1196/ANNALS.1403.015
Soren S, Jena SR, Samanta L, Parhi P (2015) Antioxidant potential and toxicity study of the cerium oxide nanoparticles synthesized by microwave-mediated synthesis. Appl Biochem Biotechnol 177:148–161. https://doi.org/10.1007/s12010-015-1734-8
Sujana MG, Chattopadyay KK, Anand S (2008) Characterization and optical properties of nano-ceria synthesized by surfactant-mediated precipitation technique in mixed solvent system. Appl Surf Sci 254:7405–7409. https://doi.org/10.1016/j.apsusc.2008.05.341
Szymanski CJ, Munusamy P, Mihai C, Xie Y, Hu D, Gilles MK, Tyliszczak T, Thevuthasan S, Baer DR, Orr G (2015) Shifts in oxidation states of cerium oxide nanoparticles detected inside intact hydrated cells and organelles. Biomaterials 62:147–154. https://doi.org/10.1016/j.biomaterials.2015.05.042
Takami S, Ohara S, Adschiri T, Wakayama Y, Chikyow T (2008) Continuous synthesis of organic-inorganic hybridized cubic nanoassemblies of octahedral cerium oxide nanocrystals and hexanedioic acid. Dalt Trans. https://doi.org/10.1039/b801099d
Waku I, Magalhães MS, Alves CO, de Oliveira AR (2021) Haloperidol-induced catalepsy as an animal model for parkinsonism: a systematic review of experimental studies. Eur J Neurosci 53:3743–3767. https://doi.org/10.1111/ejn.15222
Zavvari F, Nahavandi A, Shahbazi A (2020) Neuroprotective effects of cerium oxide nanoparticles on experimental stress-induced depression in male rats. J Chem Neuroanat 106:101799. https://doi.org/10.1016/j.jchemneu.2020.101799
Zeng L, Gowda BHJ, Ahmed MG, Abourehab MAS, Chen ZS, Zhang C, Li J, Kesharwani P (2023) Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer 22(1):1–50. https://doi.org/10.1186/S12943-022-01708-4
Zhang Y, Zhou K, Zhai Y, Qin F, Pan L, Yao X (2014) Crystal plane effects of nano-CeO2 on its antioxidant activity. RSC Adv 4:50325–50330. https://doi.org/10.1039/c4ra06214k
Acknowledgements
Mohammad is highly thankful to the Indian Council of Medical Research (ICMR), New Delhi for the financial support (scholarship) of the project (3/1/2/126/Neuro/2019-NCD-1). The author (Mohammed A.S. Abourehab) would like to thank the Deanship of scientific research at Umm Al-Qura University for supporting this work by grant code (23UQU4290565DSR032).
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors have not disclosed any competing interests.
Institutional review board statement
The animal study protocol was approved by the Institutional Animal Ethical Committee (IAEC) (Jamia Hamdard, New Delhi, India), with the approved animal study protocol 173/GO/ReBi/ S2000/CPCSEA (Approval No. 1611, 2019). The Declaration of Helsinki’s guidelines was used for performing the present study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mohammad, Khan, U.A., Saifi, Z. et al. Intranasal inorganic cerium oxide nanoparticles ameliorate oxidative stress induced motor manifestations in haloperidol-induced parkinsonism. Inflammopharmacol 31, 2571–2585 (2023). https://doi.org/10.1007/s10787-023-01274-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-023-01274-1